publication date: Jul. 17, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
Summer of 2020 was supposed to be a brief period of respite between Wave 1 and Wave 2 of COVID-19, but out of sheer stubbornness, for reasons political, or both, SARS-CoV-2 didn’t get the message.
A conference organized by the American Association for Cancer Research July 20-22 will bring together oncologists from academia, industry and government to identify ways for cancer researchers to inform studies of COVID-19.
As cases of COVID-19 surge in Florida, Lucio Gordan, managing physician and president of Florida Cancer Specialists and Research Institute, is working to increase the role of telehealth.
In early March, when Giuseppe Curigliano, an oncologist in Milan, first spoke with The Cancer Letter about COVID-19, the situation in Italy was “like being in a war zone” (The Cancer Letter, March 11, 2020).
The FDA Oncologic Drugs Advisory Committee July 14 voted 12-0 to recommend approval for belantamab mafodotin for relapsed or refractory multiple myeloma.
- ASCO opens search for chief medical officer
- Nunez-Smith named director of Center for Community Engagement and Health Equity at Yale
- Yale receives $11 million SPORE renewal for lung cancer research
- Winship glioblastoma project receives $500,000
- NICE, Flatiron to develop RWE research methodologies
- MD Anderson and Sanofi collaborate on R&D program
- Hackensack Meridian and Merck form COVID-19 research collaboration
- Cohen named regional director of Oncology Services, Southern Region at RWJBarnabas Health
- Cancer groups urge Trump to reconsider withdrawal from WHO
- St. Jude researchers create analytic tool to identify what drives tumor growth
- NCCN translates tool that gauges mental health of cancer patients
- Pfizer and BioNTech receive FDA Fast Track designation for investigational COVID-19 vaccine candidates
- Ashion Analytics receives Medicare coverage for assay for advanced solid tumors